Literature DB >> 11588039

Blood coagulation at the site of microvascular injury: effects of low-dose aspirin.

A Undas1, K Brummel, J Musial, K G Mann, A Szczeklik.   

Abstract

The sequence of coagulant reactions in vivo following vascular injury is poorly characterized. Using quantitative immunoassays, the time courses were evaluated for activation of prothrombin, factor (F)V, FXIII, fibrinogen (Fbg) cleavage, and FVa inactivation in bleeding-time blood collected at 30-second intervals from 12 healthy subjects both before and after aspirin ingestion. Prothrombin decreased at a maximum rate of 14.2 +/- 0.6 nM per second to 10% of initial values at the end of bleeding. Significant amounts of alpha-thrombin B chain appeared rapidly at 90 seconds of bleeding and increased at a maximum rate of 0.224 +/- 0.03 nM per second to a peak value of 38 nM. Kinetics of prethrombin 2 generation was almost identical. Prothrombinase concentration reached a peak value of 22 pM at 150 seconds and then decreased to 9 pM at the end of bleeding. Prothrombin fragment 1.2 (F1.2) was produced explosively (0.673 +/- 0.05 nM per second), whereas thrombin-antithrombin III (TAT) complexes were generated at a much slower rate (0.11 +/- 0.008 nM per second; P =.002). FVa light chain was detectable 30 seconds later than the heavy chain (150 seconds) and was produced at a slightly slower rate (0.027 +/- 0.001 nM per second) when compared with the heavy chain (0.032 +/- 0.002 nM per second; P =.041). The 30 000 fragment (residues 307-506) of FVa heavy chain produced by activated protein C appeared as early as at 90 seconds and increased with time. Fbg was removed from the blood shed with a high rate of 0.047 +/- 0.02 microM/s and became undetectable at approximately 180 seconds of bleeding. The velocity of FXIII activation correlated with thrombin B-chain formation. A 7-day aspirin administration (75 mg/d) resulted in significant reductions in maximum rates of (1) prothrombin removal (by 29%; P =.008); generation of alpha-thrombin B-chain (by 27.2%; P =.022), and prethrombin 2 (by 26%; P =.014); formation of F1.2 (by 31.4%; P =.009) and TAT (by 30.3%; P = 0.013); (2) release of FVa heavy chain (by 25%; P =.003) and FVa light chain (by 29.6%; P =.007); (3) Fbg depletion from solution (by 30.5%; P =.002); and (4) FXIII activation (by 28.6%; P =.003). Total amounts of the proteins studied, collected at every interval, also significantly decreased following aspirin ingestion. These results indicate that low-dose aspirin impairs thrombin generation and reactions catalyzed by this enzyme at the site of the injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588039     DOI: 10.1182/blood.v98.8.2423

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Mathematical and biological models of blood coagulation.

Authors:  T Orfeo; K G Mann
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

2.  Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients.

Authors:  Anetta Undas; Magdalena Celinska-Löwenhoff; Kathleen E Brummel-Ziedins; Jan Brozek; Andrew Szczeklik; Kenneth G Mann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-07       Impact factor: 8.311

3.  Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects.

Authors:  A Undas; B Brzezinska-Kolarz; K Brummel-Ziedins; J Musial; A Szczeklik; K G Mann
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

4.  Blood coagulation dynamics in haemostasis.

Authors:  K G Mann; T Orfeo; S Butenas; A Undas; K Brummel-Ziedins
Journal:  Hamostaseologie       Date:  2009-01       Impact factor: 1.778

Review 5.  Oral factor Xa inhibitors for the long-term management of ACS.

Authors:  James W Wisler; Richard C Becker
Journal:  Nat Rev Cardiol       Date:  2012-02-21       Impact factor: 32.419

Review 6.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Authors:  Anetta Undas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

Review 7.  Thrombin generation in hemorrhage control and vascular occlusion.

Authors:  Kenneth G Mann
Journal:  Circulation       Date:  2011-07-12       Impact factor: 29.690

8.  Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity.

Authors:  Jeremy P Wood; Jay R Silveira; Nicole M Maille; Laura M Haynes; Paula B Tracy
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113

9.  A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery.

Authors:  Pranjal H Desai; Dinesh Kurian; Nannan Thirumavalavan; Sneha P Desai; Pluen Ziu; Michael Grant; Charles White; R Clive Landis; Robert S Poston
Journal:  Anesth Analg       Date:  2009-11       Impact factor: 5.108

10.  ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial.

Authors:  Amine Boussofara; Lobna Laroussi; Hela Baccouche; Emna Bennour; Sami Kasbaoui; Hbib Triki; Ibn El Haj Zied; Ikram Kammoun; Afef Ben Halima; Faouzi Addad; Sonia Marrakchi; Neila Ben Romdhane; Salem Kachboura
Journal:  Eur J Clin Pharmacol       Date:  2020-08-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.